| Patents for C12Q 1 - Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions (300,231) |
|---|
| 09/26/2002 | WO2002074992A2 Phosphodiesterase 4d genes related to human stroke |
| 09/26/2002 | WO2002074991A2 Detection of microorganisms using inducible genes |
| 09/26/2002 | WO2002074990A1 Molecular target validation method |
| 09/26/2002 | WO2002074989A2 Disease associated polymorphism in the ctla-4 locus |
| 09/26/2002 | WO2002074988A2 Arrays and methods of use |
| 09/26/2002 | WO2002074987A2 Quantitative diagnostic analysis of hypertonia |
| 09/26/2002 | WO2002074986A2 An early pre-symptomatic prion diagnostic blood test for encephalopathies |
| 09/26/2002 | WO2002074985A2 Method of detecting macromolecular biopolymers by means of an electrode arrangement |
| 09/26/2002 | WO2002074984A2 Biosensor, device and method for detecting nucleic acids by means of at least two units for immobilizing nucleic acids |
| 09/26/2002 | WO2002074983A1 Sensor arrangement, device and method for testing active substances and/or active sites from a pharmacological point of view using an amperometer and/or potentiometer |
| 09/26/2002 | WO2002074982A1 Methods involving the use of capg as a diagnostic marker and methods for the identification of capg modulators for the treatment and prevention of osteoporosis and related disease states |
| 09/26/2002 | WO2002074981A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 09/26/2002 | WO2002074980A2 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 09/26/2002 | WO2002074979A2 Expression profiles and methods of use |
| 09/26/2002 | WO2002074969A2 Matrix attachment regions and methods for use thereof |
| 09/26/2002 | WO2002074959A2 Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1 |
| 09/26/2002 | WO2002074951A1 METHOD OF CONSTRUCTING cDNA TAG FOR IDENTIFYING EXPRESSED GENE AND METHOD OF ANALYZING GENE EXPRESSION |
| 09/26/2002 | WO2002074950A1 Method of analyzing intermolecular interaction |
| 09/26/2002 | WO2002074949A1 Preparation of calibrants and use thereof in the quantification of nucleotide sequences of interest |
| 09/26/2002 | WO2002074941A1 Reporter virus comprising heterologous envelope proteins |
| 09/26/2002 | WO2002074924A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 09/26/2002 | WO2002074918A2 T-cell polynucleotides and polypeptides |
| 09/26/2002 | WO2002074913A2 Nucleic acid-associated proteins |
| 09/26/2002 | WO2002074911A2 Identification of gene expression alterations underlying the aging process in mammals |
| 09/26/2002 | WO2002074904A2 Rearranged squamous cell carcinoma antigen genes ii |
| 09/26/2002 | WO2002074903A2 Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| 09/26/2002 | WO2002074810A2 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof |
| 09/26/2002 | WO2002074805A1 Soluble rage protein |
| 09/26/2002 | WO2002074798A2 The genome of a bifidobacterium |
| 09/26/2002 | WO2002074796A2 Histidine phosphatase interacting protein with 240kd |
| 09/26/2002 | WO2002074789A2 Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection |
| 09/26/2002 | WO2002074782A2 Isolation and purification procedure of vasopeptidase peptide inhibitors |
| 09/26/2002 | WO2002074433A2 Method and devices for applying reagents to punctiform locations |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002074328A1 Methods of treating respiratory conditions |
| 09/26/2002 | WO2002074326A2 Urocortin-iii and uses thereof |
| 09/26/2002 | WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | WO2002074239A2 Compositions and methods for the treatment and clinical remission of psoriasis |
| 09/26/2002 | WO2002074230A2 A dna molecule encoding a variant paraoxonase and uses thereof |
| 09/26/2002 | WO2002074171A1 Fluorescent cobalamins and uses thereof |
| 09/26/2002 | WO2002074157A2 A mammalian immortalized liver cell |
| 09/26/2002 | WO2002074079A2 Polynucleotide encoding a gene conferring resistance to bacillus thuringiensis toxins |
| 09/26/2002 | WO2002074048A2 P-glycoproteins and uses thereof |
| 09/26/2002 | WO2002066683A3 Optoelectronic detection system |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002062957A3 Ter sites and ter binding proteins |
| 09/26/2002 | WO2002057414A3 Leukocyte expression profiling |
| 09/26/2002 | WO2002055665A3 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
| 09/26/2002 | WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/26/2002 | WO2002042767A3 Step-wise process to recover or eliminate biological substances by flotation from underlayered colloidal medium |
| 09/26/2002 | WO2002040709A3 Genetic test for the identification of carriers of complex vertebral malformations in cattle |
| 09/26/2002 | WO2002037938A3 Method and device for selectively targeting cells within a three -dimensional specimen |
| 09/26/2002 | WO2002035232A3 Method for detecting ovarian cancer based on human kallikrein 6 (hk6) |
| 09/26/2002 | WO2002032397A8 Electroprocessing in drug delivery and cell encapsulation |
| 09/26/2002 | WO2002029084A3 Industrial-scale serum-free production of recombinant factor vii in mammalian cells |
| 09/26/2002 | WO2002026954A3 Truncated phosphodiesterase-7 polypeptides |
| 09/26/2002 | WO2002022685A3 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/26/2002 | WO2002018634A3 Arrays of immobilised biomolecules, production and use thereof |
| 09/26/2002 | WO2002016611A3 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2002000100A3 Method for separation, identification and evaluation of microbes and cells |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001095711A3 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 09/26/2002 | WO2001094600A3 Promoters for regulated gene expression |
| 09/26/2002 | WO2001092488A3 Regulation of human plc delta-1 |
| 09/26/2002 | WO2001090143A3 Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella parapertussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001081613A3 Method for the identification of active site protease inactivators |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001066793A3 Nucleic acid and oligonucleotides derived therefrom for specifically amplifying and specifically detecting aquaporin genes from vitis spec. |
| 09/26/2002 | WO2001036683A3 Method for rapid and accurate identification of microorganisms |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001023615A9 Anti-aging nucleic acid and protein targets |
| 09/26/2002 | WO2001019845A9 Cacna1g polynucleotide, polypeptide and methods of use therefor |
| 09/26/2002 | WO2001018017A9 Methods for detecting and enumerating campylobacter jejuni in environmental samples and for identifying antibiotic-resistant strains |
| 09/26/2002 | WO2001011054A9 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138872 Transgenic plants; enhanced defense mechanisms to combat plant diseases; disease resistant plants |
| 09/26/2002 | US20020138865 In vitro transfection, storage and transfer of male germ cells for generation of transgenic species & genetic therapies |
| 09/26/2002 | US20020138862 Mice show an increased insulin sensitivity, and resistance to weight gain compared to wild-type mice on same diet; screening for enzyme inhibitors; antiobesity, antidiabetic agents |
| 09/26/2002 | US20020138859 Nucleic acid sequences; use of such enzymes to produce taxanes |
| 09/26/2002 | US20020138205 Expert system for analysis of DNA sequencing electropherograms |
| 09/26/2002 | US20020137921 Oligonucleotides having chiral phosphorus linkages |
| 09/26/2002 | US20020137920 Magnetic pigment |
| 09/26/2002 | US20020137919 Using organic cations, cationic lipids, organic anions, inorganic anions, and water-miscible organic solvents in combination with an alkali or alkaline earth cation, a tetramethylammonium cation, or a polyamine |
| 09/26/2002 | US20020137917 Assay for perkinsus in shellfish |
| 09/26/2002 | US20020137915 Conformational and topological protein regulation |
| 09/26/2002 | US20020137888 Target module is prepared by binding selectively a target protein, modified to allow its detection, to a surrogate ligand that is linked to an individually detectable bead |
| 09/26/2002 | US20020137855 Universal supports for oligonucleotide synthesis |
| 09/26/2002 | US20020137719 Particulate compositions for chemical synthesis |
| 09/26/2002 | US20020137712 69109, a novel human tyrosine phosphatase and uses therefor |
| 09/26/2002 | US20020137705 Osteoporosis |
| 09/26/2002 | US20020137700 Nucleic acids; genetic engineering |
| 09/26/2002 | US20020137699 Expression systems comprising chimeric promoters with binding sites for recombinant transcription factors |
| 09/26/2002 | US20020137695 A nucleotide, e.g., 6-(beta-D-2-Deoxyribofuranosyl)-5-hydro-methyl-8H-pyrimido(4,5 -c)(1,2)pyridazin-7-one-5'-triphosphate, incorporated into a polynuceotide or an oligomucleotide; viricides; labels |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137663 The anti-neoplastic agent ET-743 inhibits trans activation by SXR |
| 09/26/2002 | US20020137661 Incubating parental polynucleotide variants under conditions to generate annealed polynucleotides of heteroduplexes, which are then exposed to a cellular DNA repair system to convert to parental variants or recombined variants |
| 09/26/2002 | US20020137222 Materials for enhancing staining of biopolymers in matrices |
| 09/26/2002 | US20020137209 Nongenotropic effect occurs due to a ligand-induced activation of the ligand binding domain and genotropic effect occurs due to a ligand-induced activation of the DNA-binding domain of a steroid receptor |